These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34125311)

  • 1. Progress in Gynecologic Cancers with Antibody Drug Conjugates.
    O'Malley DM; Calo CA
    Curr Oncol Rep; 2021 Jun; 23(8):89. PubMed ID: 34125311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
    Tolcher A; Hamilton E; Coleman RL
    Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates in the Use of Targeted Therapies for Gynecologic Cancers.
    Cantillo E; Blanc-Durand F; Leary A; Slomovitz BM; Fuh K; Washington C
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438582. PubMed ID: 38788185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antibody-Drug Conjugates in Breast Cancer and Gynecologic Cancer].
    Saito A; Yonemori K
    Gan To Kagaku Ryoho; 2024 Jul; 51(7):695-701. PubMed ID: 39191683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Drug Conjugates in Gynecologic Cancers.
    Anastasio MK; Shuey S; Davidson BA
    Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating antibody drug conjugates in the management of gynecologic cancers.
    Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
    Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates in gynecologic malignancies.
    Lee EK; Liu JF
    Gynecol Oncol; 2019 Jun; 153(3):694-702. PubMed ID: 30929824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in antibody-drug conjugates for gynecologic malignancies.
    Tymon-Rosario J; Gorman M; Richardson DL; Washington C; Santin AD
    Curr Opin Obstet Gynecol; 2023 Feb; 35(1):6-14. PubMed ID: 36484278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody drug conjugates: Progress, pitfalls, and promises.
    Mukherjee A; Waters AK; Babic I; Nurmemmedov E; Glassy MC; Kesari S; Yenugonda VM
    Hum Antibodies; 2019; 27(1):53-62. PubMed ID: 30223393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.
    McNamara B; Greenman M; Pebley N; Mutlu L; Santin AD
    Molecules; 2023 Nov; 28(21):. PubMed ID: 37959808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel antibody-drug conjugates: current and future roles in gynecologic oncology.
    Tymon-Rosario J; Zeybek B; Santin AD
    Curr Opin Obstet Gynecol; 2021 Feb; 33(1):26-33. PubMed ID: 32618744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in cancer-targeted antibody-drug conjugates.
    Bidard FC; Trédan O
    Target Oncol; 2014 Mar; 9(1):1-8. PubMed ID: 24221961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of Targeted Agents in the Treatment of Gynecologic Cancers.
    Bruce SF; Powell MA
    Curr Treat Options Oncol; 2022 Jan; 23(1):15-28. PubMed ID: 35167006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-drug conjugates for the treatment of ovarian cancer.
    Calo CA; O'Malley DM
    Expert Opin Biol Ther; 2021 Jul; 21(7):875-887. PubMed ID: 32463296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates in Gynecologic Cancer.
    Karpel HC; Powell SS; Pothuri B
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Picking the optimal target for antibody-drug conjugates.
    Mathur R; Weiner GJ
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer.
    Shim SH; Lee JY; Lee YY; Park JY; Lee YJ; Kim SI; Han GH; Yang EJ; Noh JJ; Yim GW; Son JH; Kim NK; Kim TH; Kong TW; Choi YJ; Cho A; Lim H; Jang EB; Cho HW; Suh DH
    J Gynecol Oncol; 2024 Mar; 35(2):e66. PubMed ID: 38330382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma.
    Jagadeesh D; Smith MR
    Curr Treat Options Oncol; 2016 Oct; 17(10):55. PubMed ID: 27544507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.